Congress funds diagnostic-safety research, protects patient reports from lawsuits
H.R. 9696 — Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act · Filed by Donald Beyer (D-VA) · 2 cosponsors · Introduced Jul 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a federal research and quality-improvement program focused on diagnostic errors—misdiagnoses and delayed diagnoses that harm patients and waste healthcare dollars. It creates research centers, funds training programs, establishes a patient-reporting system for diagnostic safety events (protected from lawsuits), and creates an interagency council to coordinate diagnostic-safety research across federal health agencies. Total authorized spending: ~$66.5 million over five years.
Why we flagged it
The bill's core mechanism is establishing federal research infrastructure, quality-improvement programs, and patient-safety reporting systems—all aimed at reducing diagnostic errors and improving health outcomes. It is fundamentally a public-health research and infrastructure bill, not a regulatory carve-out or industry subsidy.
What the text implies
- Patient-safety reports are explicitly protected from civil and criminal discovery, which may reduce litigation risk for providers but does not affect patients' underlying legal rights to sue—a careful balance that could shift provider behavior toward transparency.
- The bill's emphasis on AI and data-science tools for diagnostic improvement may accelerate adoption of algorithmic decision-support systems in clinical practice, with unclear long-term effects on diagnostic autonomy and liability.
The full analysis lists 4 implications of this text.
Who stands to gain
Academic medical centers and research institutions (research funding); Health IT vendors (diagnostic software and data-integration tools); Pharmaceutical and diagnostic companies (potential market for AI-enabled diagnostic tools)